Progress in the Discovery and Development of Glutamate Carboxypeptidase II Inhibitors

Overview

Journal Drug Discov Today

Specialty Pharmacology

Date 2007 Sep 11

PMID 17826690

Citations 55

Authors

Takashi Tsukamoto

Krystyna M Wozniak

Barbara S Slusher

Affiliations

Soon will be listed here.

Abstract

During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhibition in neurological disorders of glutamatergic dysregulation. This review article details key GCP II inhibitors discovered in the last decade and important findings from preclinical and clinical studies.

Citing Articles

Effects of systemic pretreatment with the NAALADase inhibitor 2-PMPA on oral methamphetamine reinforcement in C57BL/6J mice.

Fultz E, Nei A, Chi J, Lichter J, Szumlinski K Front Psychiatry. 2024; 15:1297275.

PMID: 38638417 PMC: 11024460. DOI: 10.3389/fpsyt.2024.1297275.

Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry.

Abouzayed A, Seitova K, Lundmark F, Bodenko V, Oroujeni M, Tolmachev V Front Oncol. 2023; 13:1221103.

PMID: 37829345 PMC: 10565663. DOI: 10.3389/fonc.2023.1221103.

Synthesis and Evaluation of Tc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.

Lu K, Zhang C, Zhang Z, Kuo H, Colpo N, Benard F Molecules. 2023; 28(13).

PMID: 37446782 PMC: 10343272. DOI: 10.3390/molecules28135120.

Combination of and Screening to Identify Novel Glutamate Carboxypeptidase II Inhibitors.

Temml V, Kollar J, Schonleitner T, Holl A, Schuster D, Kutil Z J Chem Inf Model. 2023; 63(4):1249-1259.

PMID: 36799916 PMC: 9976286. DOI: 10.1021/acs.jcim.2c01269.

PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.

Debnath S, Zhou N, McLaughlin M, Rice S, Pillai A, Hao G Int J Mol Sci. 2022; 23(3).

PMID: 35163083 PMC: 8835702. DOI: 10.3390/ijms23031158.